跳至主要内容
临床试验/2024-519853-12-00
2024-519853-12-00招募中3 期

Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing daily Administration as a Treatment Strategy (STATIN-PRE trial)

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau4 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2025年6月13日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
154
试验地点
4
主要终点
Days of prolongation of pregnancy between inclusion and delivery; continuous (days).

研究概览

简要总结

To assess that daily 40 mgr of oral administration of pravastatin in pregnant individuals with PE and/or IUGR between 24.0 and 29.6 weeks of gestation will prolong duration of pregnancy compared to conventional management.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Singleton fetus.
  • Between 24+0 to 29+6 weeks of gestation at the inclusion
  • Early-onset severe PE: women with a diagnosis of severe-preterm PE who are candidates for expectant management and have no clinical indication for immediate delivery, based on the clinical assessments of the attending doctors.
  • And/or IUGR: Diagnosis of early onset IUGR according to the SMFM classification with umbilical artery Doppler with absent/reversed diastolic flow; or estimated fetal weight <10th percentile plus pulsatility index (PI) of umbilical artery Doppler >95th percentil.
  • Able to give informed consent.

排除标准

  • Established maternal or fetal compromise that necessitated immediate delivery
  • Abnormal karyotype, structural abnormalities, or congenital infections.
  • Treatment with pravastatin or other statins prior to inclusion.
  • Active liver disease, including persistent and unexplained elevations of serum transaminases (3 times above the upper limit).

结局指标

主要结局

Days of prolongation of pregnancy between inclusion and delivery; continuous (days).

Days of prolongation of pregnancy between inclusion and delivery; continuous (days).

次要结局

未报告次要终点

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Alejandra Espinosa

Scientific

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

研究点 (4)

Loading locations...

相似试验